Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.
The enzyme debrisoquine 4-hydroxylase (CYP2D6), which metabolizes many widely used drugs, is highly polymorphic. The activity of the enzyme ranges between subjects from ultrafast to a complete absence. Therefore, metabolic capacity varies, producing intersubject differences in therapeutic efficacy and side effects at standard recommended doses. Up to 7% of Caucasians may demonstrate ultrarapid drug metabolism (UM) because of inherited alleles with multiplicate functional CYP2D6 genes, causing an increased amount of enzyme to be expressed. Identification of UM subjects is of potential clinical importance for adjustment of doses in drug therapy, as well as to avoid misidentification of noncompliance. In our study, we tested recently designed PCR assays for the detection of the UM genotype. We found a 3.5% prevalence of UMs carrying duplicate active CYP2D6 genes in a population consisting of 202 psychiatric patients.
Steijns
L S
LS
Department of Clinical Chemistry, Psychiatric Hospital Veldwijk, Ermelo, The Netherlands.
Van Der Weide
J
J
D019389:Cytochrome P-450 CYP2D6 / Q000097:blood / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D008875:Middle Aged; D005810:Multigene Family; D016133:Polymerase Chain Reaction / Q000379:methods*; D044465:White People
D019389:Cytochrome P-450 CYP2D6